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Ravan Napas (RN) is a traditional formula used to treat pulmonary symptoms and diseases such as coughing, breathing diﬃculty,
and asthma in traditional Uighur medicine. The purpose of this study was to investigate the anti-inﬂammatory, and immuno-
modulatory activity of RN in a well-characterized animal model of allergic asthma. Rats were sensitized with intraperitoneal (ip)
ovalbumin (OVA) and alum, and then challenged with OVA aerosols. The asthma model rats were treated with RN; saline- and
dexamethasone- (DXM-) treated rats served as normal and model controls. The bronchoalveolar lavage ﬂuid (BALF) cellular
diﬀerential and the concentrations of sICAM-1, IL-4, IL-5, TNF-α,I N F - γ, and IgE in serum were measured. Lung sections
underwent histological analysis. The immunohistochemistry S-P method was used to measure the expression of ICAM-1 and
HO-1 in the lung. RN signiﬁcantly reduced the number of inﬂammatory cells in BALF and lung tissues, decreased sICAM-1, IL-4,
IL-5, TNF-α, and IgE in serum, and increased serum INF-γ. There was a marked suppression of ICAM-1 and HO-1 expression in
the lung. Our results suggest that RN may have an anti-inﬂammatory and immuneregulatory eﬀect on allergic bronchial asthma
by modulating the balance between Th1/Th2 cytokines.
1.Introduction
Asthma is a major public health problem worldwide.
Asthma morbidity and mortality have increased in the recent
decades [1]. Bronchial asthma is a chronic inﬂammatory
disorder of the airways characterized by airﬂow obstruction,
airway inﬂammation, persistent airway hyperresponsiveness
(AHR), and airway remodeling [2]. Increasing evidence
suggeststhatmanycellsandcellularelementsplayprominent
roles in the pathogenesis of allergic asthma [3, 4]. This
pathogenesis is mediated by nonspeciﬁc inﬁltration by vari-
ous inﬂammatory cells such as eosinophils, T-lymphocytes,
macrophages, neutrophils, and epithelial cells [5, 6]. In
addition, symptoms are mediated by a wide range of com-
pounds such as histamine, cytokines, and cyclo-oxygenase
and lipoxygenase products [7].
A variety of cytokine-bronchial cell interactions play
an important role in normal host defense as well as in
the pathogenesis of inﬂammatory airway disorders such as
asthma,acuteandchronicbronchitis,andbronchiectasis[8].
Increasing clinical and experimental evidence suggests that
an imbalance between Th1 and Th2 leads to the clinical
expression of allergic disease including asthma. The Th2
cytokines such as IL-4, IL-5, and TNF-α become overly
abundant when activated by CD4
+ T cells relative to Th1
cytokine (IFN-γ), and this is seen to play a central role
in the pathogenesis of allergic asthma [9–13]. Antigen-
induced IgE production, airway inﬂammation, and airway
hyperresponsiveness have been well documented in patients
with allergic asthma and in animal models [14–18].
Adhesion of inﬂammatory cells to the bronchial epithe-
lium is the crucial step in inducing bronchial inﬂammation2 Evidence-Based Complementary and Alternative Medicine
Table 1: Plants contained in Uighur herbal formula: Ravan Napas.
Latin name Family Part used Vulgar name Uighur name
Hyssopus cuspidatus Boriss. Lamiaceae Aerial part Hyssop Zupa
Foeniculum vulgare Mill. Apiaceae Root Fennel Arpa Badian
Carthamus tinctorius L Asteraceae Seed Saﬄower Zarangza Uruki
Brassica rapa L Brassicaceae Seed Turnip mustard Qamgur Uruki
Malva verticillata L. Malvaceae Seed Mallow Binapxa Uruki
Astragalus mongholicus Bunge Fabaceae Root Vetch Katira
Ziziphus jujuba Mill Rhamnaceae Fruit Red date Qilan
Viola tianshanica Maxim Violaceae Aerial part Tienshan Violet Gul binapxa
in asthma. ICAM-1 participates by inducing the adhesion
to and migration of the inﬂammatory cells through the
endothelium [19]. Upregulation of ICAM-1 in epithelial
and endothelial cells is believed to be a hallmark of asthma
in adults [20, 21]. ICAM-1 is shed by the cell and can
be detected in plasma, serum, or bronchoalveolar lavage
ﬂuid (BALF) in a soluble form, sICAM-1. The role of
heme oxygenase (HO) in pulmonary medicine is a rapidly
emerging ﬁeld [22–24]. HO-1 can be induced by various
stimuli such as stress, endotoxins, hypoxia, and so forth.
The highly active synthesis of HO-1 proteins has been found
in bronchial epithelial cells, lung tissues, lung macrophages
and type II lung epithelial cells of asthma models [25, 26].
Expression of the HO-1 is increased within the lung tissue
in allergic airway inﬂammation, and overexpression of HO-1
could enhance allergic airway inﬂammation [27, 28].
The treatment of asthma has been improved by the
implementation of management guidelines in recent years,
with further development in the studies that identify the
mechanisms of asthma. Inhaled corticosteroids and β-2-
agonists are used as the ﬁrst line of treatment of asthma,
reducing airway inﬂammation and bronchial constriction
eﬀectively. However, the eﬀects of these drugs are not always
satisfactory in clinical practice because of local or systemic
side eﬀects [29]. Therefore, there is a place for new or
alternative approaches to the control of asthma such as
those found in complementary and alternative medicine
(CAM), and especially in traditional medical systems. With
the development of modern pharmacological and molecular
biology techniques, studying the mechanisms of CAM in
treating asthmatic diseases is increasingly important and
potentially useful.
CAM approaches include those such as traditional
Uighur medicine (TUM), which is used in Xinjiang Uighur
Autonomous Region of China. From the principle of TUM,
the pathogenesis of asthma is due to the stimulation of
Abnormal Hilit (the ﬂuids involved as the basis of traditional
Uighur medicine) in the lung tissue, which weakens natural
power factors and induces inﬂammation. Ravan Napas (RN)
is a TUM formula, which has been used for more than
2000 years [30]. RN is a herbal concoction, which has been
used under TUM principles with the ultimate goal of relief
from wheezing and reduction of frequency of attacks in
asthmatic patients. Physicians in the TUM system use RN
that has been manufactured into granules to remove the
Abnormal Hilit and to boost the body’s natural power. RN
is regarded as a potent tonic to increase energy levels and
stimulate the immune system. Several studies have focused
on its immune-regulating properties, and RN has been
shown to increase human lymphocyte proliferation, and
immunoglobulin production in normal mice [31]. Plants
related to those used in RN [32, 33] and other plants used
in traditional Asiatic medicines [34–40] have been shown
to have an eﬀect on immunomodulation and inﬂammatory
responses in experimental asthma. However, RN has not
yet been investigated for application to allergic diseases. We
used the ovalbumin- (OVA-) induced asthmatic rat model to
evaluate possible mechanisms of RN on inﬂammation and
on systemic immune responses, using OVA-induced BALF
cell proliferation, cytokines production, and expression of
ICAM-1 and HO-1 in the lung.
2. Methods
2.1. RN Preparation. The composition of RN is listed in
Table 1 and the chemicals identiﬁed in these herbs are listed
in Table 2. The constituent plants were purchased from
Xinjiang Autonomous Region Traditional Uighur Medicine
Hospital (Urumqi, China) and were authenticated by asso-
ciate chief pharmacist Anwar Talip. In accordance with the
protocol of preparation, 1kg dried herb powder was soaked
in 10L of warm distilled water for 12 hours and boiled
for 1 hour. The extract was ﬁltered and concentrated under
reduced pressure and low temperature (60
◦C) on a rotary
evaporator, dried in vacuum conditions, and stored in the
refrigerator. The yield of the extract was found to be 22.1%.
2.2. Animals and OVA-Induced Asthmatic Rat Model. Male
Wistar Rats, weighing 200–250g were purchased from
Xinjiang Medical University Animal Centre. The animals
were housed in stainless steel cages in the Good Laboratory
Practices-compliant laboratory of the Xinjiang Traditional
UighurMedicineInstitute.Theroomtemperature(22±1◦C)
and humidity (55±10%) were controlled automatically. The
experimental procedures were approved by the guidelines of
the Animal Care and Use Committee of Traditional Uighur
Medicine Institute, Xinjiang Uighur Autonomous Region.
Induction of asthma in rats has been described previously
[41]. Rats were immunized with an intraperitoneal injection
of a suspension containing 40mg of OVA (Sigma ChemicalEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Experimental protocol. Rats were immunized with intraperitoneal injection of a suspension containing 40mg ovalbumin (OVA)
and 2mg aluminium hydroxide. 15 days after the immunization, rats were challenged by exposure to an aerosol of 1% OVA in PBS for 20
minutes once daily for 8 consecutive days (days 15 to 22). Three groups were treated for 22 days after sensitization, with saline (controls),
RN1, and RN2 (RN orally at 0.25g/kg or 0.5g/kg per day). DXM group was treated with dexamethasone 10mg/kg on days 20, 21, and 22.
Co., St. Louis, MO, USA) and 2mg of aluminium hydrox-
ide (Beijing Chemical Reagent Factory). Fifteen days after
immunization, rats were challenged by exposure to a 1%
OVA in phosphate-buﬀered saline (PBS) aerosol once daily
during 20min per day for 8 consecutive days. The challenge
was carried out in a half vented metal chamber (35cm ×
25cm × 15cm) by using an ultrasonic nebulizer, Aerosol
ﬂow rate was 3mL/min. Control group rats were exposed to
nebulised sterile saline using the same method. One day after
the last challenge the blood and tissue sample were collected.
2.3. Experimental Groups and Treatments. The rats were
divided into ﬁve groups (ten rats per group): normal, OVA-
control, OVA-RN1 group, OVA-RN2 group, and Ova–DXM
group. All OVA groups were sensitized and challenged with
OVA as described above. (Figure 1) OVA-control rats were
administered saline orally for 22 days after ﬁrst sensitization.
OVA-RN1 and OVA-RN2 were two RN dosage treatment
groups, administered with RN orally for 22 days after ﬁrst
sensitization at the dose of 0.25g/kg (RN1) and 0.5g/kg
(RN2) per day, respectively. Ova–DXM rats were adminis-
tered Dexamethasone (DXM) on days 20, 21, and 22, before
challenge, at the dose of 10mg/kg.
2.4.MeasurementofSerumsICAM-1,IL-4,IL-5,TNF-α,INF -
γ,a n dI g e .Rats were anesthetized with an intraperitoneal
injection of sodium pentobarbitone (100μg/kg), blood was
collected and centrifuged at 4◦C (3000rpm) for 10min, and
theserumwasstoredat −80
◦Cformeasurementofcytokines
and IgE. ELISA kits from R&D Systems were employed for
themeasurementofsICAM-1,IL-4,IL-5,TNF-α,INF -γ,and
IgE.
2.5. BALF Preparation and Cell Diﬀerential Counts. After
blood collection, the trachea was cannulated and the right
bronchi were tied for histological studies. Bronchoalveolar
lavage ﬂuid (BALF) was collected by lavaging the left lung
via the trachea with 15mL of ice-cold PBS. After ﬁve
lavages, approximately 10mL of BALF were recovered and
centrifuged at 4◦C (1500rpm) for 10 minutes. The cells in
the BALF were resuspended in 100μL of PBS for total and
relative leukocyte counts using a hemocytometer. The cells
in the BALF were resuspended in normal saline after a brief
hypotonic exposure to lyse red blood cells, then immediately
placedonthehemocytometer,leftunmovedfor3–5minutes,
and then counted in 10-square chambers.
2.6. Histological Analysis. After sacriﬁce, noninﬂated lungs
were removed, ﬁxed with 10% buﬀered formalin, and
processed in a standard manner. Tissue sections were stained
with hematoxylin-eosin and examined microscopically. Peri-
bronchial cells were counted using a ﬁve-point scoring
system to estimate the severity of leukocyte inﬁltration. The
leukocyte scoring was examined in three independent ﬁelds
of lung section from each rat. Mean scores were obtained
from ten rats. The scoring system was 0, no cells; 1, a few
cells; 2, a ring of cells 1 cell layer deep; 3, a ring of cells 2–4
cell layers deep; and 4, a ring of cells more than 4 cell layers
deep.
2.7. Immunohistochemistry Analysis. To identify the source
of HO-1 and ICAM-1 positive cells, immunohistochemistry
staining was performed. Antibodies were diluted 1:200
with 1% normal goat serum (NGS) in PBS. Lung sections
were sequentially incubated overnight at 4◦C in the dark
with rabbit anti-HO-1 or sheep anti-ICAM-1, followed by
biotin-labelled antibody to rabbit IgG or sheep IgG and
incubated for 30min in streptavidin-peroxide, coloured
with 3,3-diaminobenzidine (DAB) then sealed with neutral
gum. The expression of ICAM-1 and HO-1 was located in
the cytoplasm. Brown-yellow granules were considered as
positive expression. The scoring system was the number of
the positive staining cells: 0, no cells; 1, 0 ∼ 10 cells; 2,
11 ∼ 24 cells; 3, 25 ∼ 49; 4, 50 ∼ 74 cells; and 5, >75 cells.
All histology and immunohistochemical analyses were done
blind to treatment group.
2.8. Statistical Analysis. The statistical signiﬁcance of any
diﬀerence was determined by one-way ANOVA followed by
Tukey’s protected t-tests when ANOVA was signiﬁcant. The
data are expressed as mean ± S.E.M. The SPSS statistical
softwarepackage(Version10.0,Chicago,IL)wasusedforthe
statistical analysis.4 Evidence-Based Complementary and Alternative Medicine
Table 2: Chemical composition of the plants contained in Uighur herbal formula: Ravan Napas.
Plant Major chemical components References
H. cuspidatus aerial
part Essential oil: germacrenes B and D, hexadecanoic acid, (+)-transcaryophyllene, (+)-spathulenol Ablizl 2009 [42]
F. vulgare fruit
transanethole, p-anisaldehyde, chlorogenic acid, and quercetin-3-O-β-D-glucuronide
Bilia 2000 [43]
Kitajima 1998
[44–46]
Ishikawa 1998
[47]
Ishikawa 1999
[48]
Kitajima 1999
[49]
Ono 1995 [50]
Ono 1996 [51]
De Marino 2007
[52]
Water-soluble constituents:
alkyl glycosides, p-hydroxyphenylpropylene glycol glycosides, phenylpropanoid glycosides, benzyl
alcohol derivative glycosides, phenylethanoid and its glycoside, threo-epoxyanethole glycoside,
fenchane-, norfenchane-type monoterpenoid glycosides, menthane-, thujane-, camphane-type
monoterpenoids, and monoterpenoid alcohols.
Monoterpene glycosides: β-D-glucopyranosides of (1S,2R,4S)-2,4-dihydroxy-1,8-cineole-2-O,
(1R,4R,6R)-4,6-dihydroxy-1,8-cineole-6-O, (1R,4R,6R)-4,6-dihydroxy-1,8-cineole-4-O,
(1S,2R,4R,6S)-2,6-dihydroxy-1,8-cineole-2-O and (1S,2R,4S,5R)-2,5-dihydroxy-1,8-cineole-2-O
Zizybeoside I, icaviside A4, syringin, sinapyl alcohol 1,3 -di-O-β-D-glucopyranoside,
threo-anethole glycol, and erythro-anethole glycol glycosides.
Stilbene trimers: 11a-O-β-D-glucopyranoside, 13b-O-β-D-glucopyranoside,
11a,13b-di-O-β-D-glucopyranoside, 11a,13b,13c-tri-O-β-D-glucopyranoside of cis-miyabenol C
Cis-miyabenol C 11a-O-β-d-glucopyranosyl-(1→6)-β-d-glucopyranoside, cis-miyabenol C
11a,13c-di-O-β-d-glucopyranoside.
C. tinctorius seed
Serotonin derivatives, lignans, and ﬂavonoids.
Koyama 2006
[53]
Kim 2007 [54]
Ahmed 2000
[55]
Phenolic compounds: matairesinol 4 -o-β-D-glucoside, 8 -hydroxyarctigenin 4 -0-β-D-glucoside,
matairesinol, 8 -hydroxyarctigenin, N-feruloylserotonin 5-O-β-D-glucoside,
N-(p-coumaroyl)-serotonin-5-O-β-D-glucoside, N-feruloylserotonin, N-(p-coumaroyl)serotonin,
luteolin 7-O-β-D-glucoside, luteolin, acacetin 7-O-β-glucuronide, and acacetin
Acacetin 7-O-β-D-apiofuranosyl-(1  → 6 )-O-β-D-glucopyranoside together with previously
i s o l a t e dk a e m p f e r o l7 - O - β-D-glucopyranoside, acacetin 7-O-α-L-rhamnopyranoside, and
acacetin.
B. rapa seed Isothiocyanates: 3-butenyl isothiocyanate. Taveira 2009
[56]
M. verticillata seed Polysaccharides: β-1,3- and β-1,6-linked D-galactosyl residues acidic polysaccharide (MVS-VI)
and β-1,3-linked D-glucose, and D-galactose residues neutral polysaccharide (MVS-I).
Tomoda 1992
[57]
Shimizu 1991
[58]
A. mongholicus root
Triterpene saponins, isoﬂavonoids, and polysaccharides.
Zhang 2007 [59]
Chu 2010 [60]
Han 2007 [61]
Bian 2006 [62]
Yu 2005 [63]
Wang 2008 [64]
Subarnas 1991
[65]
Shimizu 1991
[66]
Yan 2005 [67]
Methanolic extract: cyclolanostane-type saponins including 8 astragaloside malonates, and
malonylastragaloside I.
Astragalosides I, II, IV, acetylastragaloside I, isoastragaloside I isoastragaloside II,
astramembrannin II, afrormosin, calycosin, calycosin-7-O-β-D-glucoside, daucosterol
formononetin, formononetin-7-O-β-D-glucoside,
formononetin-7-O-β-D-glucoside-6  -O-malonate,
2 ,4 -dimethoxy-3 -hydroxyisoﬂavan-6-O-β-glucopyranoside,
(6aR,11aR)9,10-dimethoxypterocarpan-3-O-β-D-glucoside,
(6aR,11aR)3,9-dimethoxy-10-hydroxypterocarpan, (3R)8,2 -dihydroxy-7,4 -dimethoxyisoﬂavan,
ononin, pinitol, β-sitosterol.
Calycosin-7-O-β-D-glucoside,
(6aR,11aR)-3-hydroxy-9,10-dimethoxypterocarpan-3-O-β-D-glucoside, and
3,9-di-O-methylnissolin
4-hydroxy-5-hydroxymethyl-[1,3]dioxoian-2,6 -spirane-5 ,6 ,7 ,8 -tetrahydro-indolizine-3 -
carbaldehyde
(HDTIC-1 and -2).
Isoﬂavanoids: 7-O-methylisomucronulatol, isomucronulatol 7,2 -di-O-glucoside,
5 -hydroxyisomucronulatol 2 ,5 -di-O-glucoside, and
(3R)-7,2 -dihydroxy-3 ,4 -dimethoxyisoﬂavan-7-O-β-D-glucoside α-arabino-β-3,6-galactan-type
acidic polysaccharide
LectinEvidence-Based Complementary and Alternative Medicine 5
Table 2: Continued.
Plant Major chemical components References
Z. jujube fruit
Water and ethanol extracts:
Terpenoids: ceanothic acid, alphitolic acid, zizyberanal acid, zizyberanalic acid, zizyberanone,
epiceanothic acid, ceanothenic acid, betulinic acid, oleanolic acid, ursolic acid, 2α-hydroxyursolic
acid and zizyberenalic acid,
(2S,3S,4R,8E)-2-[(2 R)-2 -hydroxy-tetracosanoyl]-8-octadecene-1,3,4-triol and its
1-O-β-D-glucopyranosyl derivate, maslinic acid, 3β,6β-stigmast-4-en-3,6-diol, β-sitosterol,
daucosterol, tetracosanoic acid, and heptadecanoic acid.
Guo 2009
[68–70]
Pawlowska 2009
[71]
Flavonoids: kaempferol 3-O-robinobioside, kaempferol 3-O-rutinoside, quercetin
3-O-robinobioside, quercetin 3-O-rutinoside, quercetin 3-O-β-D-xylosyl-(1-2)-α-L-rhamnoside,
quercetin 3-O-α-L-arabinosyl-(1-2)-α-L-rhamnoside, and rutin.
V. tianshanica aerial
part
Daucosterol and ﬂavonoids: isorhamnetin 3-O-β-glucoside, kaempferol, kaempferol
7-O-β-D-glucopyranoside, kaempferol 3-O-β-D- glucopyranoside, and quercetin. Yu 2009 [72]
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Figure 2: Eﬀect of Ravan Napas (RN) on the recruitment of inﬂammatory cells in BALF obtained from OVA-induced rat model of asthma. Rat
Bronchoalveolar Lavage Fluid (BALF) was harvested during the 24h after last OVA challenge. All rats were sensitized with OVA: (a) total
leucocytes, (b) lymphocytes and neutrophils, and (c) eosinophils. Normal: rats sensitized with OVA and challenged with saline. Control:
rats sensitized and challenged with OVA. DXM: OVA-sensitized and challenged rats treated with Dexamethasone (10mg/kg). RN-1: OVA-
sensitized and challenged rats treated with RN (0.25g/kg/day). RN-2: OVA-sensitized and challenged rats treated with RN (0.5g/kg/day).
Data are expressed as mean ±S.E.M., n = 10 rats per treatment group.    P<. 01 versus Normal; ∗∗∗P<. 01 versus Control.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of Ravan Napas (RN) on pulmonary inﬂammation in OVA-induced rat model of asthma. Lung tissues were obtained on the
day after the last OVA challenge. Tissues were stained with hematoxylin and eosin (H&E, 400x) (a). The inﬂammatory cell inﬁltration in
the lung tissues was scored as described in the method section (b). Normal: rats sensitized with OVA and challenged with saline. Control:
rats sensitized and challenged with OVA. DXM: OVA-sensitized and challenged rats treated with Dexamethasone (10mg/kg). RN-1: OVA-
sensitized and challenged rats treated with RN (0.25g/kg/day). RN-2: OVA-sensitized and challenged rats treated with RN (0.5g/kg/day).
Data are expressed as mean ±S.E.M., n = 10 rats per treatment group.    P<. 01 versus Normal; ∗∗∗P<. 01 versus Control.
3. Results
3.1. Total Leukocytes and Eosinophils in BALF. RN signiﬁ-
cantly decreased the number of leukocytes in BALF in com-
parison with the control group (Figures 2(a) and 2(b) P<
.01versusnormal).Diﬀerentialleukocytecountsshowedthat
RN decreased the number of neutrophils, eosinophils, and
lymphocytes in comparison with the control group (P<. 01)
(Figure 2(c)).
3.2. Pathological Inﬂammation in Lung Tissue. Rats from
each group were autopsied, and sections of the major organs
were examined by a pathologist unaware of their origin. No
gross or histological abnormalities were observed in tissues
other than the lung. As previously described, lungs from
normal (sham-treated)/antigen-sensitized/challenged mice
contained large numbers of peribronchial and perivascular
eosinophils (data not shown). The lung tissue obtained
from ovalbumin-induced asthmatic rats was character-
ized by dense peribronchial inﬂammation due to leuko-
cyte inﬁltration and mucus hyperproduction by goblet
cells within the bronchi when compared with normal
tissue. This inﬂammation resulted in the narrowing of
the bronchi (Figure 3(a)). RN extract signiﬁcantly reduced
the degree of inﬂammatory cell inﬁltration (P<. 05)
(Figure 3(b)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀect of Ravan Napas (RN) on sICAM-1 and total IgE concentration in serum of OVA-induced rat model of asthma. Blood was
sampled and serum obtained 24h after last OVA challenge. sICAM-1 and total IgE were measured by ELISA as described in the materials
and methods section. (a): sICAM-1 concentrations; (b): IgE concentrations; Normal: rats sensitized with OVA and challenged with saline.
Control: rats sensitized and challenged with OVA. DXM: OVA-sensitized and challenged rats treated with Dexamethasone (10mg/kg).
RN-1: OVA-sensitized and challenged rats treated with RN (0.25g/kg/day). RN-2: OVA-sensitized and challenged rats treated with RN
(0.5g/kg/day). Data are expressed as mean ±S.E.M., n = 10 rats per group.    P<. 01 versus Normal; ∗∗∗P<. 01 versus Control.
3.3. Serum sICAM-1, IgE, IL-4, IL-5, TNF-α,a n dI N F - γ. The
serum concentration of sICAM-1 and total IgE in model
group signiﬁcantly increased following the induction of
asthma(P<. 01)(Figure 4).OVAinducedIL-4,IL-5,TNF-α,
andIgEelevationsinserum(Figure 5).RNinhibitedsICAM-
1, and IgE increases in serum (P<. 05) (Figure 4). IL-4, IL-5,
and TNF-α levels in serum were reduced in RN-treated rats
compared with model group rats (Figure 5).
The INF-γ concentration was reduced by OVA exposure
and increased signiﬁcantly in RN-treated rats. INF-γ con-
centrations after RN1 and RN2 were increased signiﬁcantly
compared with control and normal controls (Figure 5).
3.4. Expression of ICAM-1 and HO-1 in Lung. RN strongly
inhibited the increased expression of ICAM-1 and HO-1
following the induction of asthma (P<. 05) (Figure 6) when
compared with model control rats.
4. Discussion
It has been reported that some antiasthma CAM formu-
las have therapeutic eﬀects on allergic asthma [73–76].
Inhibition of the regional inﬂammatory response through
the reduction of antigen-induced inﬂammatory cells and
inﬂammatory cytokines production is a main therapeutic
objective in the treatment of asthma. In this study, a rat
model of allergic asthma was developed, the lung tissues
examined, and BAL analysed to assess the eﬀect of RN
on airway inﬂammation in experimental asthma. Pathology
analysisdocumentedthat22-dayRNadministrationreduced
the allergic inﬂammatory inﬁltration in the lung tissues,
reduced OVA-induced sICAM-1, IL-4, IL-5, TNF-α,a n dI g E
elevations in serum, and increased INF-γ concentration. We
also found that RN markedly suppressed increased ICAM-1
and HO-1 expression in lung tissue of allergic asthma rats.
Collectively, all of these results demonstrated that RN is a
potent agent in inﬂammatory pulmonary diseases.
The precise mechanisms of chronic airway inﬂammation
in asthma are incompletely known but are considered to
be dependent on the sustained inﬁltration and activa-
tion of many inﬂammatory cells including lymphocytes,
eosinophils, basophils, and macrophages, followed by syn-
thesis and release of a variety of proinﬂammatory mediators
and cytokines [77, 78]. Th2 lymphocytes are the key orches-
trators of this inﬂammation, initiating and propagating
inﬂammationthroughthereleaseoftheircytokines,IL-4,IL-
5, and TNF-α in turn recruiting and activating eosinophils,
the eﬀector cells in asthma [79–82]. The inﬁltration of
eosinophils into the airways has been linked to the produc-
tion of IL-5, which is important for eosinophil proliferation,
activation, and migration [83]. IL-4 induces IgE isotype
switching in B lymphocytes [84] and mucus production by
goblet cells [85], as well as upregulation of the expression of
adhesion molecules required for inﬂammatory cell recruit-
ment [79]. TNF-α is also an important chemoattractant for
the recruitment of eosinophils into the lungs [10, 86]. It
is also a potent modulator of immune and inﬂammatory
response.
Migration of leukocytes from circulation into tissue is
dependent upon the interaction with adhesion molecules
expressed on the cell surface and endothelium. ICAM-1
and its soluble form, sICAM-1, play important roles in
the development of airway/lung inﬂammation in asthma.
When inﬂammation occurs, the expression of ICAM-1 on
the bronchial epithelium and lung vascular endothelium is
signiﬁcantly increased and thereby increases the adhesion of8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of Ravan Napas (RN) on IL-4, IL-5, INF-α,a n d
INF-γ in serum of OVA-induced rat model of asthma. Blood was
sampled and serum obtained 24h after last OVA challenge. IL-4,
IL-5, TNF-α,a n dI N F - γ were analyzed by ELISA as described in the
materials and methods section. Normal: rats sensitized with OVA
and challenged with saline. Control: rats sensitized and challenged
with OVA. DXM: OVA-sensitized and challenged rats treated with
Dexamethasone (10mg/kg). RN-1: OVA-sensitized and challenged
rats treated with RN (0.25g/kg/day). RN-2: OVA-sensitized and
challenged rats treated with RN (0.5g/kg/day). Data are expressed
asmean±S.E.M.,n = 10ratspergroup.    P<. 01versusNormal;
∗∗∗P<. 01 versus Control.
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Figure 6:EﬀectofRNontheexpressionofICAM-1andHO-1inlung
tissueofOVA-inducedratmodelofasthma.Wistarratlungtissuewas
obtained 24 hours after last Ova challenge. Immunohistochemistry
was performed as described in materials and methods section.
Expression of ICAM-1 and HO-1 in the lung tissues was scored
as described in Section 2. Normal: rats sensitized with OVA and
challenged with saline. Control: rats sensitized and challenged
with OVA. DXM: OVA-sensitized and challenged rats treated with
Dexamethasone (10mg/kg). RN-1: OVA-sensitized and challenged
rats treated with RN (0.25g/kg/day). RN-2: OVA-sensitized and
challenged rats treated with RN (0.5g/kg/day). Data are expressed
asmean±S.E.M.,n = 10ratspergroup.    P<. 01versusNormal;
∗∗∗P<. 01 versus Control.
eosinophils on the epithelium [87–89] .T h e r ei sac l o s ec o r -
relation between high concentration of sICAM-1 and high
expression of ICAM-1 with the severity of asthma in patients
and asthmatic rats [19, 89, 90]. Higher concentrations of
sICAM-1 in serum and BALF reﬂect the upregulation of
ICAM-1 expression in allergic bronchial asthma, and these
high concentrations may contribute to the pathogenesis of
atopic bronchial asthma [91, 92].
The eosinophil is regarded as a key mediator of the
pathology and abnormal physiology of bronchial asthma
[93]. It has been suggested that eosinophils contribute to
tissue damage [94, 95] and airway inﬂammation. AHR also
may play an important role in recruitment of T cells to
the lung during airway allergic responses by modulating
chemokine and cytokine production in the lung. In most
asthma phenotypes, there are increases in eosinophils in
the tissues, blood and bone marrow and, in general, raised
numbers correlating with disease severity [96]. Speciﬁcally,
TNF-α is an important chemoattractant for the recruitment
of eosinophils into the lungs [10, 86]. It is also a potent
modulator of immune and inﬂammatory response. IL-
5 uniquely and speciﬁcally participates in the control of
eosinophil production and diﬀerentiation [10]. Attenuated
synthesis of TNF-α and IL-5 could therefore relieve allergic
responses caused by eosinophils.
Our results showed that serum concentrations of IL-
4, IL-5, TNF-α, and sICAM-1 were signiﬁcantly reduced
in allergic rats after RN administration. In addition, RN
inhibited the pulmonary accumulation of leukocytes and
eosinophils in rats, which is parallel to the decrease of IL-
4, IL-5, TNF-α, and sICAM-1 in serum and overexpression
of ICAM-1 and HO-1 in allergic lung tissue (Figure 7). Our
study is similar to previous reports and consistent with
reports of increased ICAM-1 expression in the lungs of
patients with asthma [97]. Cell count analyses and histologi-
calresultscorroboratethepositivecorrelationsoftheinﬂam-
matory cells of BALF with the extent of total inﬂammatory
cells, eosinophil, lymphocyte, and macrophage inﬁltration
in lung tissues and BALF. In this study, the inhibitory eﬀect
of RN on inﬂammation in allergic rats was accompanied
by a signiﬁcant decrease in Th2 cytokines, sICAM-1, and
ICAM-1 overexpression. Our results suggest that RN may
play a key role in blocking the recruitment of leukocytes
and eosinophils in lung through Th2-cytokines dependent
pathway, much as dexamethasone.
As expected, DXM, one of the most potent cor-
ticosteroids, also suppressed antigen-induced AHR and
eosinophilic inﬂammation in this model. However unlike
RN, DXM suppressed Th1 responses (IFN-γ)a sw e l la s
Th2 (IL-4, IL-5, and TNF-α) responses. In this study, the
administration of RN resulted in a downregulation of the
Th2 cytokines IL-4, IL-5, and TNF-α; however, there was
signiﬁcant concomitant increase in the levels of the Th1
cytokine IFN-γ in serum. In addition, IFN-γ levels were
higher in the RN group than those in the model group or
Normal group. This type of immunoregulation may prove
to be more beneﬁcial than Th1 cytokines (IFN-γ and IL-
12) or Th1 adjuvant therapy, which may cause undesirable
inﬂammation because of higher-than-normal levels of Th1Evidence-Based Complementary and Alternative Medicine 9
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Figure 7: Main anti-inﬂammatory and immunoregulatory targets of Ravan Napas (RN) in allergic asthma. This ﬁgure illustrates the cascade
of activations and inactivations resulting from exposure to allergen after sensitization in asthma, from exposure of Antigen-presenting cells
(APC) to activation of mast cells and neutrophils, activation of Th2 cells liberating ICAM, interleukins, and TNFα, inactivation of Th1 cells
releasing INFγ, and so forth. From the results reported, RN, as indicated, acts on various pathways implicated in the bronchial response
to antigens: stimulation of Th1, inactivation of Th2, decreased ICAM and HO-1 expression, decreased IgE production, and decreased
recruitment of neutrophils and other inﬂammatory cells.
cytokines. These ﬁndings suggest that RN and perhaps other
antiasthma formulas may oﬀer some clinical advantages over
corticosteroids because they are less likely to increase the
patient’s susceptibility to infection.
Oxidative stress is thought to induce the inﬂammation of
many chronic diseases [98]. During asthma, reactive oxygen
species (ROS)—including superoxide anion—is produced in
tissues, from oxidative injury [24]. One of these defence
mechanisms is the induction of a stress-response protein,
HO-1. HO-1 catalyses the initial and rate limiting step of
heme metabolism. In asthma attacks, since the activity and
protein synthesis of HO-1 are greatly increased, its products,
bilirubin, free iron, and CO would also be increased [99,
100]. CO can act as second messenger [101]. Although
studies suggest a cytoprotective eﬀect of HO-1, its over-
expression might also contribute to asthma inﬂammation.
The following mechanism might be involved: HO-1 and CO
accelerate the release of proinﬂammatory mediators such as
IL-5 and TNF-α in mast cells and eosinophils thus increasing
the hyperresponsiveness of the airways [102]. Bilirubin, if
produced excessively, would disturb the biomembrane. Free
iron, if it accumulates, could become cytotoxic. So we can
assume that during asthma, HO-1 has dual eﬀects [103]. We
also found that low levels of HO-1 expression are protective.
Moderate levels of expression decrease its cytoprotective
eﬀect, whereas high expression actually worsens the damage.
The experimental results showed that the expression of HO-
1 was signiﬁcantly higher in the model than in the control
group. Interestingly, similar results have been reported with
extracts from plats close to those used in RN [32, 33].
In conclusion, RN suppressed antigen-induced inﬂam-
mation in this rat model of asthma. This eﬀect was accompa-
nied by reduction of leukocytes, eosinophilic inﬂammation,
and speciﬁc downregulation of Th2 responses, inhibiting the
expression of ICAM-1 and HO-1 in lung tissue. This study
suggests that Uighur herbal medicines, such as RN, should
be further explored for possible use for treatment of asthma
and allergy.
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